Self-assembly is an autonomous process where components organize themselves into structures via noncovalent interactions without human intervention. Ultrashort amphiphilic peptides are typical self-assembly molecules with specific sequence motifs which consist of three to seven amino acids. Due to their amphiphilic structure which carries a dominant hydrophobic tail and a polar head group, these peptides can self-assemble to construct nanofibrous scaffolds system to form hydrogels, organogels or aerogels. The nanofibrous scaffolds formed by amphiphilic peptides are very similar to the fiber structure found in collagen which plays an essential role in extracellular matrix showing the potential of applying these peptide scaffolds together in culturing native human cells. Thus the derivate of amphiphilic peptides depsipeptide in which we replaced one amide bond with an ester bond is also worthwhile to explore a novel penitential material for Tissue Engineering. At the same time, because of the perfect biocompatibility of amphiphilic peptides made up of natural l-amino acids and also the excellent gelation properties providing a solution for zinc dendrite growth in Zn batteries, it will be also meaningful to combine the rationally designed peptide gelation system to Zn batteries. This dissertation describes how to characterize and use ultrashort amphiphilic depsipeptide for tissue engineering and use ultrashort amphiphilic peptide for the electrolyte of Zn batteries. The first chapter provides us with an introduction to self-assembly material, 3D bioprinting, and Zn batteries. The second chapter introduces a novel method to synthesize the depsipeptide fully based on solid phase peptide synthesis (SPPS) and also shows the different properties, especially the gelation behavior by clarifying its mechanism via doing the characterization of depsipeptide. At the end of the second chapter, depsipeptide is proved to be a potential material in 3D bioprinting. The third chapter reveals how we synthesized and characterized the amphiphilic peptide and applied it to the Zn batteries. The cycling stability got promoted compared with bard Zn batteries in symmetrical Zn-Zn cells while the formation of Zn dendrite was also suppressed. The promising results suggest peptide gelation systems are promising electrolytes for use in Zn batteries.

Techn. Hochsch., Diss., 2000--Aachen.

Caseinolytic protease (ClpP) is a cylindrical protease forming the core of protein degradation machinery in eubacteria. ClpP is tightly regulated and is non-functional without a member of the Clp-ATPases. A new class of antibiotics, termed ADEPs, bind to ClpP and allow for activation without the Clp-ATPases; leading to cell death. A more efficient synthetic route to the ADEPs utilizing solid-phase peptide synthesis was investigated. A linear peptide was synthesized, however attempts to close the depsipeptidic macrocycle via macrolactonization failed. Further attempts of assembling a branched depsipeptide for ring closure via a macrolactamization resulted in products that were not stable to cleavage conditions. A group of molecules termed Activators of Self-Compartmentalizing Proteases (ACP) were identified through a screen for activity towards ClpP. Compound ACP1 was synthesized along with twelve analogs and their activity towards ClpP evaluated. The project resulted in a compound with a higher activity than its natural product counterpart.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

This research focuses on the understanding and engineering of nonribosomal peptide biosynthetic pathways in Streptomyces coelicolor CH999, Escherichia coli BAP1 and Saccharomyces cerevisiae BJ5464-NpgA. The biosynthetic systems of indigoidine from bacteria and beauvericin/bassianolide from fungi were studied in this research. The production of these valuble products was significantly increased by enhancing their synthetic pathway with metabolic engineering approaches. Indigoidine is a bacterial natural product with antioxidant and antimicrobial activities. Its bright blue color resembles the industrial dye indigo, thus representing a new natural blue dye that may find uses in industry. Indigo is a dark blue crystalline powder and has been known for more than 4,000 years. It is commonly used to dye cotton yarn for the production of denim cloth to make blue jeans but the chemical synthesis of indigo requires harsh conditions and use of a strong base. Indigoidine is a new natural blue dye that is vi assembled from two molecules of L-glutamine under the catalysis of indigoidine synthetase. We identified a novel indigoidine synthetic gene from the genome of Streptomyces chromofuscus ATCC 49982. The successful heterologous expression of Sc-indC in E. coli BAP1 give us a pretty good yield of indigoidine under the optimized conditions. The production of this blue dye was then further improved by introducing two additional genes, sc-indB and glnA, into the biosynthetic pathway. Beauvericins and bassianolide are anticancer natural products from fungi and are assembled by corresponding iterative nonribosomal peptide synthetases. The beauvericin (BbBEAS) and bassianolide (BbBSLS) synthetases were successfully reconstituted in S. cerevisiae BJ5464-NpgA, leading to the production of beauvericins and bassianolide, respectively. The production of beauvericins was significantly improved by co-expression of BbBEAS and ketoisovalerate reductase (KIVR). To better understand the synthetic strategy of fungal iterative NRPs, the module/domain of BbBSLS and BbBEAS were dissected and reconstituted in S. cerevisiae. The result shows the intermodular linker is essential for the reconstitution of the separate modules and the domain swapping results indicated the fungal iterative NRPSs use a liner biosynthetic route which is different than bacterial iterative NRPs. The in vitro reactions of C2 and C3 with monomer/dimer/trimerN-acetylcysteamines demonstrated that C2 forms the amide bond and C3 catalyses the synthesis of the ester bond. Beauvericin could be reconstituted in vitro through co-reaction of C2(BbBEAS) and C3(BbBEAS) with D-Hiv-SNAC and N-Me-L-Phe- SNAC. This work also provides an unprecedented tool for engineering fungal iterative NRPSs to yield ‘unnatural’ cyclooligomer depsipeptides with varied chain lengths.

Caseinolytic protease (ClpP) is a cylindrical protease forming the core of protein degradation machinery in eubacteria. ClpP is tightly regulated and is non-functional without a member of the Clp-ATPases. A new class of antibiotics, termed ADEPs, bind to ClpP and allow for activation without the Clp-ATPases; leading to cell death. A more efficient synthetic route to the ADEPs utilizing solid-phase peptide synthesis was investigated. A linear peptide was synthesized, however attempts to close the depsipeptidic macrocycle via macrolactonization failed. Further attempts of assembling a branched depsipeptide for ring closure via a macrolactamization resulted in products that were not stable to cleavage conditions. A group of molecules termed Activators of Self-Compartmentalizing Proteases (ACP) were identified through a screen for activity towards ClpP. Compound ACP1 was synthesized along with twelve analogs and their activity towards ClpP evaluated. The project resulted in a compound with a higher activity than its natural product counterpart.

京都大学 / 0048 / 新制・課程博士 / 博士(薬科学) / 甲第21049号 / 薬科博第92号 / 新制||薬科||10(附属図書館) / 京都大学大学院薬学研究科医薬創成情報科学専攻 / (主査)教授 大野 浩章, 教授 竹本 佳司, 教授 高須 清誠 / 学位規則第4条第1項該当 / Doctor of Pharmaceutical Sciences / Kyoto University / DFAM

No description available.

<p>Cancer immunotherapy aims at reversing the immunosuppressive tumor environment and enhancing anti-tumor immunity. This thesis comprises studies on murine models for prostate (TRAMP-C2) and bladder (MB49) cancer with the aim to explore if the introduction of an adenoviral vector expressing CD40 ligand (AdCD40L) can induce anti-tumor immune responses.</p><p>We show in subcutaneous mouse models that AdCD40L treatment suppresses tumor growth. Bladder cancer is known to secrete immunosuppressive IL-10 which may inhibit T cell function. We show that introducing AdCD40L into mouse bladder tumors inhibits IL-10 production and reverses immunosuppression. AdCD40L-transduced mouse prostate cancer cells showed caspase activation and reduced cell viability. Vaccination with CD40L-modified prostate cancer cells induces anti-tumor responses and protects mice against rechallenge with native TRAMP-C2 cells. In order to enhance AdCD40L therapy, we explored the possibility of combining it with the histone deacetylase inhibitor FK228, also known as depsipeptide. We show that FK228 upregulates coxsackie and adenovirus receptor expression and thereby enhances adenoviral-mediated CD40L expression in both murine and human prostate cancer cells. Increasing amounts of FK228 or AdCD40L reduces prostate cancer cell viability, while the combined treatment gives at least an additive therapeutic effect. Moreover, we show that AdCD40L transduction of prostate cancer cells induces endogenous CD40 expression and sensitize them for CD40L-mediated therapy.</p><p>In order to conduct prostate-specific gene therapy, prostate-specific promoters can be used to drive transgene expression. However, there are no reports on prostate-specific promoters that are transcriptionally active in mouse cells. Here we show that by using the two-step transcription activation system (TSTA), we can enhance the activity of a recombinant human promoter sequence and obtain activity in mouse prostate cancer cells as well. This finding paves the way for future studies of prostate-specific gene therapy in immunocompetent mouse models.</p>

Cancer immunotherapy aims at reversing the immunosuppressive tumor environment and enhancing anti-tumor immunity. This thesis comprises studies on murine models for prostate (TRAMP-C2) and bladder (MB49) cancer with the aim to explore if the introduction of an adenoviral vector expressing CD40 ligand (AdCD40L) can induce anti-tumor immune responses. We show in subcutaneous mouse models that AdCD40L treatment suppresses tumor growth. Bladder cancer is known to secrete immunosuppressive IL-10 which may inhibit T cell function. We show that introducing AdCD40L into mouse bladder tumors inhibits IL-10 production and reverses immunosuppression. AdCD40L-transduced mouse prostate cancer cells showed caspase activation and reduced cell viability. Vaccination with CD40L-modified prostate cancer cells induces anti-tumor responses and protects mice against rechallenge with native TRAMP-C2 cells. In order to enhance AdCD40L therapy, we explored the possibility of combining it with the histone deacetylase inhibitor FK228, also known as depsipeptide. We show that FK228 upregulates coxsackie and adenovirus receptor expression and thereby enhances adenoviral-mediated CD40L expression in both murine and human prostate cancer cells. Increasing amounts of FK228 or AdCD40L reduces prostate cancer cell viability, while the combined treatment gives at least an additive therapeutic effect. Moreover, we show that AdCD40L transduction of prostate cancer cells induces endogenous CD40 expression and sensitize them for CD40L-mediated therapy. In order to conduct prostate-specific gene therapy, prostate-specific promoters can be used to drive transgene expression. However, there are no reports on prostate-specific promoters that are transcriptionally active in mouse cells. Here we show that by using the two-step transcription activation system (TSTA), we can enhance the activity of a recombinant human promoter sequence and obtain activity in mouse prostate cancer cells as well. This finding paves the way for future studies of prostate-specific gene therapy in immunocompetent mouse models.